Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and donor stem cell trans…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Fludarabine (Fludarabine)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24